What Can the US Learn From the UK's Approach to Drug Diversion?

Drug diversion is a global challenge, but not every country approaches it the same way.In this episode of Drug Diversion Insights, Terri welcomes Mark Jackson, whose work in the United Kingdom is roughly equivalent to the FDA's Office of Criminal Investigations in the United States. Together, they explore the similarities and differences between how the UK and US regulate controlled substances, investigate diversion, and address medication security across healthcare settings.This wide-ranging conversation covers:How the UK classifies controlled substances using Classes A, B, and CHow UK classifications compare to the US scheduling systemMark's journey into diversion prevention and investigationsDiversion risks in pharmaceutical manufacturing and healthcare settingsWhy benzodiazepines appear more frequently in UK diversion cases than opioidsDifferences in opioid prescribing practices between the UK and USCultural differences in pharmacy operations and medication accessA UK perspective on American drive-thru pharmacies• Lessons both countries can learn from one another in preventing diversionWhether you work in pharmacy, healthcare compliance, medication safety, healthcare security, or diversion monitoring, this episode offers valuable insight into how two healthcare systems tackle many of the same challenges in very different ways.If you've ever wondered how drug diversion prevention looks on the other side of the Atlantic, this conversation provides a fascinating comparison.More from Rxpert Solutions